# Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

> **NCT03154515** · PHASE4 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 445 (actual)

## Conditions studied

- Common Cold
- Influenza, Human
- Acute Respiratory Infection

## Interventions

- **DRUG:** Ingavirin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03154515
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-10
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2017-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154515, "Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03154515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*